查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594337

单株抗体市场：按产品类型、生产类型、适应症和最终用户划分 - 2025-2030 年全球预测

Monoclonal Antibodies Market by Source Type (Chimeric, Human, Humanized), Production Type (In Vitro, In Vivo), Indication, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年单株抗体市值为1,262.6亿美元，预计2024年将达到1,418.1亿美元，复合年增长率为12.41%，到2030年将达到2,864.3亿美元。

单株抗体 (mAb) 是实验室製造的分子，旨在作为抗体的替代，增强或模拟免疫系统对细胞的攻击。由于它对特定抗原具有高度特异性，因此是治疗癌症、自体免疫疾病、感染疾病等多种疾病的高度可靠的治疗方法。单株抗体的需求在于其标靶特异性，从而减少副作用并提高治疗效果。其应用范围广泛，在疾病管理、诊断工具和研究药物方面具有治疗用途。最终用途范围广泛，包括製药和生物技术领域、医院和研究机构，推动了各种临床和实验环境的需求。市场成长受到慢性病增加、基因研究进步和医疗保健支出增加等因素的显着影响。然而，高昂的製造成本、严格的监管以及可能的副作用都限制了市场的扩张。专注于这些创新治疗方法的生物製药公司的激增为市场相关人员提供了机会。此外，亚太地区由于医疗基础设施的改善和投资的增加，市场正在扩大，前景良好。为了利用这些机会，公司应该投资先进的生物加工技术以降低成本并提高产量比率，并建立策略联盟进行研发。同时，市场参与企业必须克服生物相似药竞争和製造复杂性等挑战。创新领域包括双特异性和多特异性抗体等新型单株抗体、增强的递送机制以及单株抗体与人工智慧等新技术的整合以实现个人化治疗。因此，由于技术进步和不断增长的医疗保健需求，单株抗体市场充满活力并不断发展，需要策略远见和适应性策略来实现永续成长和竞争优势。

主要市场统计
基准年[2023] 1262.6亿美元
预测年份 [2024] 1418.1亿美元
预测年份 [2030] 2864.3亿美元
复合年增长率（%） 12.41%

市场动态：揭示快速发展的单株抗体市场的关键市场洞察

单株抗体市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 扩大具有成本效益的生物相似药单株抗体的传播
    • 癌症和其他慢性疾病的发生率上升
    • 随着技术先进的遗传平台的出现，基因组学的研究和开发活动不断增加
  • 市场限制因素
    • 治疗性单株抗体价格昂贵
  • 市场机会
    • 年度核准显着增加
    • 改善供应链和分销网络
  • 市场挑战
    • 当前製造和精製工艺的局限性

波特五力：驾驭单株抗体市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解单株抗体市场的外部影响

外部宏观环境因素在塑造单株抗体市场表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解单株抗体市场的竞争状况

单株抗体市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵单株抗体市场供应商绩效评估

FPNV定位矩阵是评估单株抗体市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘单株抗体市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对单株抗体市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 单株抗体作为具有成本效益的生物相似药越来越受欢迎
      • 癌症和其他慢性疾病的发生率上升
      • 基因组学研究和开发活动的增加以及技术先进的遗传平台的出现
    • 抑制因素
      • 治疗性单株抗体价格昂贵
    • 机会
      • 年度核准数量显着增加
      • 改善供应链和分销网络
    • 任务
      • 目前製造和精製工艺的局限性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依来源类型分類的单株抗体市场

  • 嵌合体
  • 人类
  • 人性化
  • 鼠

第七章依生产类型分類的单株抗体市场

  • 体外
  • In vivo

第八章以适应症分類的单株抗体市场

  • 自体免疫疾病
  • 癌症
  • 感染疾病
  • 发炎疾病
  • 微生物病

第九章单株抗体市场：依最终用户分类

  • 医院
  • 调查机构

第十章美洲单株抗体市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区单株抗体市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲单株抗体市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie, Inc.
  • ADC Therapeutics SA
  • Almac Group Limited
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-ED54C46E8B1E

The Monoclonal Antibodies Market was valued at USD 126.26 billion in 2023, expected to reach USD 141.81 billion in 2024, and is projected to grow at a CAGR of 12.41%, to USD 286.43 billion by 2030.

Monoclonal antibodies (mAbs) are laboratory-made molecules designed to serve as substitute antibodies that can enhance or mimic the immune system's attack on cells. They are highly specific to a particular antigen, making them a reliable therapeutic tool in the treatment of various diseases, including cancers, autoimmune disorders, and infectious diseases. The necessity of monoclonal antibodies is driven by their target specificity, which reduces side effects and increases treatment efficacy. Applications are broad, encompassing therapeutic use in disease management, diagnostic tools, and as research agents. The end-use scope spans across the pharmaceutical and biotechnology sectors, hospitals, and research institutes, driving demand across a spectrum of clinical and experimental settings. Market growth is significantly influenced by factors such as increased prevalence of chronic diseases, advancements in genetic research, and rising healthcare expenditure. However, high production costs, stringent regulatory frameworks, and potential side effects pose limitations to market expansion. A rapidly increasing number of biopharmaceutical companies focusing on these innovative therapies presents opportunities for market stakeholders. Additionally, expanding markets in the Asia-Pacific region, driven by improved healthcare infrastructure and increased investment, offer lucrative prospects. To capitalize on these opportunities, companies should invest in advanced bioprocessing technologies to reduce costs and improve yield, while also engaging in strategic collaborations for research and development. Meanwhile, market players must navigate challenges such as biosimilar competition and manufacturing complexity. Areas of innovation include novel mAb formats such as bispecific and multispecific antibodies, enhancing delivery mechanisms, and integrating mAbs with emerging technologies like artificial intelligence to personalize treatments. Consequently, the mAb market is dynamic, with continuous evolution driven by technological advancements and growing healthcare demands, warranting strategic foresight and adaptive strategies for sustainable growth and competitive advantage.

KEY MARKET STATISTICS
Base Year [2023] USD 126.26 billion
Estimated Year [2024] USD 141.81 billion
Forecast Year [2030] USD 286.43 billion
CAGR (%) 12.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Monoclonal Antibodies Market

The Monoclonal Antibodies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
    • Rising incidence of cancer and other chronic diseases
    • Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
  • Market Restraints
    • Pricing of therapeutic mAbs are high
  • Market Opportunities
    • Substantial increase in the number of approvals per year
    • Improvements in supply chain and distribution network
  • Market Challenges
    • Limitation in current manufacturing and purification processes

Porter's Five Forces: A Strategic Tool for Navigating the Monoclonal Antibodies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Monoclonal Antibodies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Monoclonal Antibodies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Monoclonal Antibodies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Monoclonal Antibodies Market

A detailed market share analysis in the Monoclonal Antibodies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Monoclonal Antibodies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Monoclonal Antibodies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Monoclonal Antibodies Market

A strategic analysis of the Monoclonal Antibodies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie, Inc., ADC Therapeutics SA, Almac Group Limited, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source Type, market is studied across Chimeric, Human, Humanized, and Murine.
  • Based on Production Type, market is studied across In Vitro and In Vivo.
  • Based on Indication, market is studied across Autoimmune Diseases, Cancer, Infectious Diseases, Inflammatory Diseases, and Microbial Diseases.
  • Based on End-User, market is studied across Hospitals and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
      • 5.1.1.2. Rising incidence of cancer and other chronic diseases
      • 5.1.1.3. Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
    • 5.1.2. Restraints
      • 5.1.2.1. Pricing of therapeutic mAbs are high
    • 5.1.3. Opportunities
      • 5.1.3.1. Substantial increase in the number of approvals per year
      • 5.1.3.2. Improvements in supply chain and distribution network
    • 5.1.4. Challenges
      • 5.1.4.1. Limitation in current manufacturing and purification processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Monoclonal Antibodies Market, by Source Type

  • 6.1. Introduction
  • 6.2. Chimeric
  • 6.3. Human
  • 6.4. Humanized
  • 6.5. Murine

7. Monoclonal Antibodies Market, by Production Type

  • 7.1. Introduction
  • 7.2. In Vitro
  • 7.3. In Vivo

8. Monoclonal Antibodies Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cancer
  • 8.4. Infectious Diseases
  • 8.5. Inflammatory Diseases
  • 8.6. Microbial Diseases

9. Monoclonal Antibodies Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutes

10. Americas Monoclonal Antibodies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Monoclonal Antibodies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Monoclonal Antibodies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie, Inc.
  • 3. ADC Therapeutics SA
  • 4. Almac Group Limited
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. Biogen Inc.
  • 8. Bristol Myers Squibb Company
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Johnson & Johnson Services, Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 2. MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MONOCLONAL ANTIBODIES MARKET DYNAMICS
  • TABLE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023